- Home
- MGNX vs IROQ Comparison
MGNX vs IROQ Comparison
Compare MGNX & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- IROQ
- Stock Information
- Founded
- MGNX 2000
- IROQ 1883
- Country
- MGNX United States
- IROQ United States
- Employees
- MGNX N/A
- IROQ N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- IROQ Savings Institutions
- Sector
- MGNX Health Care
- IROQ Finance
- Exchange
- MGNX Nasdaq
- IROQ Nasdaq
- Market Cap
- MGNX 87.7M
- IROQ 75.0M
- IPO Year
- MGNX 2013
- IROQ 2011
- Fundamental
- Price
- MGNX $1.61
- IROQ $24.58
- Analyst Decision
- MGNX Hold
- IROQ
- Analyst Count
- MGNX 9
- IROQ 0
- Target Price
- MGNX $5.33
- IROQ N/A
- AVG Volume (30 Days)
- MGNX 1.3M
- IROQ 1.3K
- Earning Date
- MGNX 08-05-2025
- IROQ 08-28-2025
- Dividend Yield
- MGNX N/A
- IROQ 1.63%
- EPS Growth
- MGNX N/A
- IROQ 69.23
- EPS
- MGNX N/A
- IROQ 1.05
- Revenue
- MGNX $154,050,000.00
- IROQ $25,099,000.00
- Revenue This Year
- MGNX N/A
- IROQ N/A
- Revenue Next Year
- MGNX N/A
- IROQ N/A
- P/E Ratio
- MGNX N/A
- IROQ $23.47
- Revenue Growth
- MGNX 255.31
- IROQ 12.02
- 52 Week Low
- MGNX $0.99
- IROQ $16.40
- 52 Week High
- MGNX $5.77
- IROQ $25.76
- Technical
- Relative Strength Index (RSI)
- MGNX 59.02
- IROQ 51.73
- Support Level
- MGNX $1.34
- IROQ $24.28
- Resistance Level
- MGNX $1.65
- IROQ $25.00
- Average True Range (ATR)
- MGNX 0.11
- IROQ 0.24
- MACD
- MGNX 0.04
- IROQ -0.01
- Stochastic Oscillator
- MGNX 91.40
- IROQ 76.54
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.